PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33558541-0	2021	Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide.	enzalutamide	104-116	transmembrane serine protease 2	Homo sapiens	24-31	
33558541-3	2021	Among these drugs, a second-generation antiandrogen agent, enzalutamide, was proposed because it reduces the expression of transmembrane serine protease 2 (TMPRSS2), a key component mediating SARS-CoV-2-driven entry, in prostate cancer cells.	enzalutamide	59-71	transmembrane serine protease 2	Homo sapiens	123-154	
33558541-3	2021	Among these drugs, a second-generation antiandrogen agent, enzalutamide, was proposed because it reduces the expression of transmembrane serine protease 2 (TMPRSS2), a key component mediating SARS-CoV-2-driven entry, in prostate cancer cells.	enzalutamide	59-71	transmembrane serine protease 2	Homo sapiens	156-163	
34210968-0	2021	The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells.	enzalutamide	17-29	transmembrane serine protease 2	Homo sapiens	44-51	
34210968-4	2021	We show here that treatment with the antiandrogen enzalutamide-a well-tolerated drug widely used in advanced prostate cancer-reduces TMPRSS2 levels in human lung cells and in mouse lung.	enzalutamide	50-62	transmembrane serine protease 2	Homo sapiens	133-140	
31638934-0	2019	TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model.	enzalutamide	39-51	transmembrane serine protease 2	Homo sapiens	0-7	
31638934-4	2019	We hypothesize that enzalutamide treatment will be more effective in cells/tumors with TMPRSS2-ERG translocations because these tumors have increased AR signaling.	enzalutamide	20-32	transmembrane serine protease 2	Homo sapiens	87-94